ArticleInternational ophthalmology2025
EZH2 expression in corneal and conjunctival intraepithelial neoplasia and squamous cell carcinoma: a potential marker for diagnosis.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWithout histological analysis, the diagnosis and grading of ocular surface squamous neoplasia (OSSN) are challenging in clinical differentiation between malignant and premalignant lesions. This study examined EZH2 expression in corneal and conjunctival epithelial benign hyperplasia, intraepithelial neoplasia (CIN) and squamous cell carcinoma (SCC), and evaluated its relationship with clinicopathological features for diagnostic value.
methodsImmunohistochemistry was used to detect EZH2 protein expression in 13 cases of benign corneal and conjunctival epithelial benign hyperplasia, 66 CIN cases, and 26 SCC cases. Statistical analysis was performed to assess the relationship between EZH2 expression and clinicopathological features including age, gender, laterality, tumor diameter and histopathological differentiation.
resultsThe mean age of all patients was 58.4 ± 16.56 years, with a predominance of males. A positive EZH2 expression rate as high as 96.2% (101/105) was observed. The EZH2 intensity, ranging from negative (-) to strong (+ + +), showed significant statistical differences among the groups (p = 0.000) and was notably elevated in SCC compared to the other four groups (p < 0.05). Mean immunoreactive scores were 2.15 ± 1.21 for epithelial benign hyperplasia, 2.60 ± 1.95 for CINI, 3.76 ± 3.56 for CINII, 4.47 ± 3.33 for CINIII (including carcinoma in situ), 7.62 ± 2.80 for SCC, respectively. High EZH2 immunoexpression showed no association with age, gender or laterality but correlated significantly with tumor diameter and histopathological differentiation (p = 0.010, p = 0.000).
conclusionEZH2 expression increases with CIN grade and is highest in SCC, indicating its involvement in tumor development and invasion. These findings support its potential as a diagnostic and prognostic indicator, as well as a therapeutic target.
Indexed as
Identifiers
40451935What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.